| Primary |
| Atrial Fibrillation |
33.9% |
| Supraventricular Tachycardia |
15.3% |
| Atrial Tachycardia |
10.2% |
| Tachycardia |
9.3% |
| Product Used For Unknown Indication |
6.8% |
| Arrhythmia |
3.4% |
| Urinary Tract Infection |
2.5% |
| Ventricular Arrhythmia |
2.5% |
| Hot Flush |
1.7% |
| Hypertension |
1.7% |
| Hypothyroidism |
1.7% |
| Nerve Block |
1.7% |
| Nodal Arrhythmia |
1.7% |
| Ventricular Extrasystoles |
1.7% |
| Wolff-parkinson-white Syndrome |
1.7% |
| Allergy Test |
0.8% |
| Blood Cholesterol Increased |
0.8% |
| Depression |
0.8% |
| Diverticulitis |
0.8% |
| Diverticulum |
0.8% |
|
| Toxicity To Various Agents |
39.3% |
| Product Quality Issue |
8.2% |
| Ventricular Tachycardia |
8.2% |
| Vision Blurred |
6.6% |
| Drug Eruption |
3.3% |
| Neutropenia |
3.3% |
| Overdose |
3.3% |
| Throat Irritation |
3.3% |
| Transient Ischaemic Attack |
3.3% |
| Tremor |
3.3% |
| Vomiting |
3.3% |
| Alveolitis |
1.6% |
| Blindness |
1.6% |
| Completed Suicide |
1.6% |
| Dehydration |
1.6% |
| Diarrhoea |
1.6% |
| Drug Resistance |
1.6% |
| Dry Skin |
1.6% |
| Electrocardiogram Abnormal |
1.6% |
| Electrocardiogram Qrs Complex Prolonged |
1.6% |
|
| Secondary |
| Product Used For Unknown Indication |
39.0% |
| Atrial Fibrillation |
21.4% |
| Tachycardia |
6.3% |
| Hypertension |
5.0% |
| Drug Use For Unknown Indication |
4.4% |
| Supraventricular Tachycardia |
4.4% |
| Atrial Flutter |
3.8% |
| Arrhythmia |
1.9% |
| Cardiac Dysrhythmias |
1.9% |
| Osteoarthritis |
1.9% |
| Blood Cholesterol Increased |
1.3% |
| Bradycardia |
1.3% |
| Depression |
1.3% |
| Nodal Arrhythmia |
1.3% |
| Tachycardia Foetal |
1.3% |
| Ventricular Tachycardia |
1.3% |
| Allergy Test |
0.6% |
| Cardiac Fibrillation |
0.6% |
| Diarrhoea |
0.6% |
| Hypoglycaemia |
0.6% |
|
| Toxicity To Various Agents |
14.3% |
| Nausea |
9.5% |
| Syncope |
9.5% |
| Substance Abuse |
7.1% |
| Angioedema |
4.8% |
| Completed Suicide |
4.8% |
| Drug Interaction |
4.8% |
| Electrocardiogram Qt Prolonged |
4.8% |
| Palpitations |
4.8% |
| Right Ventricular Hypertrophy |
4.8% |
| Supraventricular Tachycardia |
4.8% |
| Tremor |
4.8% |
| Ventricular Tachycardia |
4.8% |
| Cardiac Failure Congestive |
2.4% |
| Drug Eruption |
2.4% |
| Drug Ineffective |
2.4% |
| Electrocardiogram Repolarisation Abnormality |
2.4% |
| Feeling Jittery |
2.4% |
| Foetal Growth Restriction |
2.4% |
| Haemorrhage |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.4% |
| Atrial Fibrillation |
22.4% |
| Hypertension |
9.9% |
| Drug Use For Unknown Indication |
4.9% |
| Arrhythmia |
4.4% |
| Rheumatoid Arthritis |
4.2% |
| Cerebrovascular Accident Prophylaxis |
3.5% |
| Blood Cholesterol Increased |
3.5% |
| Cardiac Disorder |
2.3% |
| Anxiety |
2.1% |
| Diabetes Mellitus |
2.1% |
| Pain |
2.1% |
| Anticoagulant Therapy |
1.7% |
| Depression |
1.7% |
| Hypothyroidism |
1.7% |
| Type 2 Diabetes Mellitus |
1.7% |
| Blood Pressure |
1.4% |
| Pulmonary Arterial Hypertension |
1.4% |
| Arthritis |
1.3% |
| Gastrooesophageal Reflux Disease |
1.3% |
|
| Memory Impairment |
7.5% |
| Headache |
6.7% |
| Syncope |
6.7% |
| Atrial Fibrillation |
5.8% |
| Myalgia |
5.8% |
| Pain In Extremity |
5.8% |
| Vomiting |
5.8% |
| Drug Ineffective |
5.0% |
| Drug Interaction |
5.0% |
| Rash |
5.0% |
| Tendonitis |
5.0% |
| Tremor |
5.0% |
| Atrial Flutter |
4.2% |
| Nausea |
4.2% |
| Palpitations |
4.2% |
| Pruritus |
4.2% |
| Skin Disorder |
4.2% |
| Death |
3.3% |
| Diarrhoea |
3.3% |
| Fatigue |
3.3% |
|
| Interacting |
| Product Used For Unknown Indication |
34.9% |
| Atrial Tachycardia |
14.0% |
| Hypertension |
14.0% |
| Atrial Fibrillation |
7.0% |
| Hepatitis C |
7.0% |
| Arrhythmia |
2.3% |
| Atrial Flutter |
2.3% |
| Complex Regional Pain Syndrome |
2.3% |
| Diverticulum |
2.3% |
| Hypercholesterolaemia |
2.3% |
| Hypothyroidism |
2.3% |
| Local Anaesthesia |
2.3% |
| Menopause |
2.3% |
| Urinary Tract Infection |
2.3% |
| Ventricular Arrhythmia |
2.3% |
|
| Drug Interaction |
15.4% |
| Palpitations |
15.4% |
| Convulsion |
7.7% |
| Eye Movement Disorder |
7.7% |
| International Normalised Ratio Increased |
7.7% |
| No Adverse Event |
7.7% |
| Rash |
7.7% |
| Renal Failure Acute |
7.7% |
| Toxicity To Various Agents |
7.7% |
| Ventricular Arrhythmia |
7.7% |
| Ventricular Tachycardia |
7.7% |
|
